Current Headlines

  1. AB SCIEX Announces Immunosuppressants Kit For Use By Doctors In Europe To Help Care For Organ Transplant Patients

    Every organ transplant patient in the world faces the potential danger of his/her body rejecting a new organ, such as a heart, kidney or liver. Immunosuppressant drugs are required to help prevent rejection

  2. Genedata Biologics 4.0 Enables Large-Scale Design, Synthesis, And Testing Of Bispecific Antibodies

    Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Biologics™ 4.0, the latest version of its enterprise workflow support and data management solution for biologics R&D

  3. Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio®▼ (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive disease (severe VOD or sVOD) in patients over one month of age undergoing haematopoietic stem cell transplantation (HSCT) therapy

  4. Convergence Pharmaceuticals (‘Convergence’ Or ‘The Company’) - Convergence And Evotec Form Integrated Pain Alliance

    Convergence Pharmaceuticals Holdings Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has entered into a research alliance with Evotec, a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies

  5. Kindred Bio And X-Body Announce An Exclusive Collaboration For Discovery Of Antibodies For Companion Animal Health

    Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and Kindred Bio will develop and commercialize these antibodies

  6. DiscoveRx And Collaborators Present Data On Safety, Bioactivities Of Wide Range Of Substances To Society Of Toxicology

    DiscoveRx Corporation, through its wholly owned Bioseek subsidiary, today announced new findings regarding the safety and toxicity of a variety of chemicals, pharmaceuticals and other materials, tested via the Predictive Tox panel in the company's BioMAP® Systems platform

  7. Simulations Plus Releases ADMET Predictor Version 7.0

    Simulations Plus, Inc., a leading provider of consulting services and software for pharmaceutical discovery and development, recently announced that it has released version 7.0 of its best-in-class ADMET Predictor molecular property prediction software

  8. Tempo Bioscience Launches Human Cellular And Biosensor Products

    Tempo Bioscience Inc ("Tempo"), a biotech startup based in San Francisco, California, announces the launch of its central nervous system (CNS) product line of human cell types for in vitroresearch and development (R&D) and chemical testing

  9. Grace Introduces Disposable Purification Solution To Lower Cost And Accelerate Drug Development For Biotech

    W. R. Grace & Co. has introduced ProVance pre-packed columns, a portfolio of products for cost-effective purification of biologic drugs, specifically monoclonal antibodies (mAbs). Monoclonal antibodies are key therapeutic agents used to treat rheumatoid arthritis, cancer and other diseases

  10. Frost & Sullivan: Live Cell Imaging Revolutionises Disease Diagnostics And Drug Discovery

    Tremendous advances in electronics, optics, fluorescent tools, and molecular biology have made live cell imaging technologies more accessible to life scientists looking to understand biological dynamics and visualize cellular events in organisms.